Expert Interview of Specialist Insights in Urothelial Cancer: Optimal Management for NMIBC and MIBC Patients (2 of 2)

Natalia Carballo, MD
MD Anderson Cancer Center Madrid
Madrid, Spain

The therapeutic landscape for urothelial cancer has undergone significant transformation in recent years, with the addition of PD1/PD-L1 targeting immune checkpoint inhibitors and novel targeted therapies and antibody-drug conjugates (ADCs) adding to the complexity of treatment options available for patients throughout the course of their disease. The optimal sequencing of treatments depends on an understanding of the relevance of different pathological subtypes of the disease and of the latest clinical evidence and guidelines that support the use of different therapies. These considerations were discussed in detail during the recent ‘Urothelial Cancer Preceptorship’, in which experts in the field provided a detailed grounding of the disease process and management from diagnosis through to salvage treatments of advanced disease.

View the Expert Interview on Specialist Insights in Urothelial Cancer from each faculty member which features specific expert insights on the topics related to the faculty presentations and the key questions discussed during the preceptorship. The enduring materials aimed to enable clinicians to integrate the latest advances and use of novel therapies for advanced urothelial cancer into safe and effective patient care. The presentation slides of the Preceptorship are also available to download.

Based on the Expert Interview of Specialist Insights and Preceptorship held on 18 and 19 September 2024.